MARKET

ACER

ACER

Acer Therapeutic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.380
+0.190
+5.96%
Pre Market: 3.160 -0.22 -6.51% 07:37 03/04 EST
OPEN
3.285
PREV CLOSE
3.190
HIGH
3.450
LOW
3.164
VOLUME
400
TURNOVER
--
52 WEEK HIGH
5.84
52 WEEK LOW
1.080
MARKET CAP
48.37M
P/E (TTM)
-1.6309
1D
5D
1M
3M
1Y
5Y
BRIEF-Acer Therapeutics Files For Sale Of Up To 4.04 Mln Common Shares By Lincoln Park Capital Fund
reuters.com · 13h ago
10-K: ACER THERAPEUTICS INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. The following discussion of our...
Edgar Online - (EDG = 10Q, 10K) · 2d ago
Acer Therapeutics EPS misses by $0.09
Acer Therapeutics (ACER): Q4 GAAP EPS of -$0.50 misses by $0.09.Cash and equivalents of $5.8M.Stock -2%Press Release
Seekingalpha · 2d ago
BRIEF-Acer Therapeutics Reports Q4 Loss Per Share Of $0.50
reuters.com · 2d ago
Acer Therapeutics Targeting ACER-001 Pre-New Drug Application Meeting With FDA in 2Q
Acer Therapeutics Targeting ACER-001 Pre-New Drug Application Meeting With FDA in 2Q
Dow Jones · 2d ago
Acer Therapeutics 4Q Loss $6.24M >ACER
Acer Therapeutics 4Q Loss $6.24M >ACER
Dow Jones · 2d ago
Acer Therapeutics 4Q Loss/Shr 50c >ACER
Acer Therapeutics 4Q Loss/Shr 50c >ACER
Dow Jones · 2d ago
Acer Therapeutics Q4 EPS $(0.50) Up From $(0.51) YoY
Acer Therapeutics (NASDAQ:ACER) reported quarterly losses of $(0.50) per share. This is a 1.96 percent increase over losses of $(0.51) per share from the same period last year.
Benzinga · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACER. Analyze the recent business situations of Acer Therapeutic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACER stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 64
Institutional Holdings: 2.80M
% Owned: 19.54%
Shares Outstanding: 14.31M
TypeInstitutionsShares
Increased
2
59.23K
New
13
574.46K
Decreased
8
23.13K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Independent Director
Stephen Aselage
President/Chief Executive Officer/Director
Christopher Schelling
Chief Financial Officer
Harry Palmin
Vice President - Finance/Controller
Jason Kneeland
Vice President
Stacey Bain
Vice President
Terrie Kellmeyer
Vice President
John Klopp
Vice President
Kristin Mulready
Vice President
Matt Seibt
Other
William Andrews
Director of Marketing
Kim Tharaldsen
Independent Director
Jason Amello
Independent Director
Hubert Birner
Independent Director
John Dunn
Independent Director
Michelle Griffin
Independent Director
Luc Marengere
No Data
  • All
  • Financials
  • Insiders
More
About ACER
Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

Webull offers kinds of Acer Therapeutics Inc stock information, including NASDAQ:ACER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACER stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACER stock methods without spending real money on the virtual paper trading platform.